Literature DB >> 12647844

Post-mortem findings in familial partial lipodystrophy, Dunnigan variety.

W A Haque1, F Vuitch, A Garg.   

Abstract

AIMS: Familial partial lipodystrophy, Dunnigan variety (FPLD), is an autosomal dominant disorder due to missense mutations in the lamin A/C gene and is characterized by gradual loss of subcutaneous fat from the extremities and trunk, fat accumulation in the head, neck and intra-abdominal areas, insulin resistance and its metabolic complications. We studied autopsy findings in two patients with FPLD to determine fat distribution and organ involvement.
RESULTS: Patient 1, a 66-year-old woman with the R482Q mutation, had diabetes mellitus, dyslipidaemia, and coronary artery disease and died suddenly. Autopsy confirmed the typical body fat distribution and further revealed excess fat deposition in the subpectoral regions extending to the axillae, in the axillary lymph nodes and in the retroperitoneum. Atherosclerotic vascular disease including old infarcts of the myocardium, temporal lobe and kidneys were noted. Severe amyloidosis of the pancreatic islets and grouped muscle atrophy of the quadriceps and diaphragmatic muscles were present. Patient 2, a 29-year-old woman belonging to a pedigree with the R62G mutation, died of hyperlipidaemia-induced acute pancreatitis. Autopsy of patient 2 revealed extensive pancreatitis, hepatic steatosis and polycystic ovaries.
CONCLUSIONS: Our study confirms typical body fat distribution and describes new sites of excess fat deposition. Our data show predisposition to atherosclerosis and polycystic ovaries and suggest that pancreatic amyloidosis may underlie development of hyperglycaemia in FPLD patients.

Entities:  

Mesh:

Year:  2002        PMID: 12647844     DOI: 10.1046/j.1464-5491.2002.00796.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  12 in total

1.  Adipokines and the insulin resistance syndrome in familial partial lipodystrophy caused by a mutation in lamin A/C.

Authors:  S P Y Wong; M Huda; P English; A Bargiota; J P H Wilding; A Johnson; R Corrall; J H Pinkney
Journal:  Diabetologia       Date:  2005-11-17       Impact factor: 10.122

Review 2.  Successful Treatment of an Unusual Case of FPLD2: The Role of Roux-en-Y Gastric Bypass-Case Report and Literature Review.

Authors:  Sharon Grundfest-Broniatowski; JingLiang Yan; Matthew Kroh; Holly Kilim; Andrew Stephenson
Journal:  J Gastrointest Surg       Date:  2016-10-24       Impact factor: 3.452

Review 3.  Genetic determinants of hepatic steatosis in man.

Authors:  Amanda J Hooper; Leon A Adams; John R Burnett
Journal:  J Lipid Res       Date:  2011-01-18       Impact factor: 5.922

4.  LMNA mutations, skeletal muscle lipid metabolism, and insulin resistance.

Authors:  Michael Boschmann; Stefan Engeli; Cedric Moro; Angelika Luedtke; Frauke Adams; Kerstin Gorzelniak; Gabriele Rahn; Anja Mähler; Kerstin Dobberstein; Antje Krüger; Saskia Schmidt; Simone Spuler; Friedrich C Luft; Steven R Smith; Hartmut H-J Schmidt; Jens Jordan
Journal:  J Clin Endocrinol Metab       Date:  2010-02-03       Impact factor: 5.958

5.  Renal complications of lipodystrophy: A closer look at the natural history of kidney disease.

Authors:  Baris Akinci; Sadiye Mehtat Unlu; Ali Celik; Ilgin Yildirim Simsir; Sait Sen; Banu Nur; Fatma Ela Keskin; Basak Ozgen Saydam; Nilufer Kutbay Ozdemir; Banu Sarer Yurekli; Bekir Ugur Ergur; Melda Sonmez; Tahir Atik; Atakan Arslan; Tevfik Demir; Canan Altay; Ulku Aybuke Tunc; Tugba Arkan; Ramazan Gen; Erdal Eren; Gulcin Akinci; Aslihan Arasli Yilmaz; Habib Bilen; Samim Ozen; Aygul Celtik; Senay Savas Erdeve; Semra Cetinkaya; Huseyin Onay; Sulen Sarioglu; Elif Arioglu Oral
Journal:  Clin Endocrinol (Oxf)       Date:  2018-05-17       Impact factor: 3.478

6.  The role of LMNA in adipose: a novel mouse model of lipodystrophy based on the Dunnigan-type familial partial lipodystrophy mutation.

Authors:  Kari M Wojtanik; Keith Edgemon; Srikant Viswanadha; Brigette Lindsey; Martin Haluzik; Weiping Chen; George Poy; Marc Reitman; Constantine Londos
Journal:  J Lipid Res       Date:  2009-02-05       Impact factor: 5.922

7.  A case of Dunnigan-type familial partial lipodystrophy (FPLD) due to lamin A/C (LMNA) mutations complicated by end-stage renal disease.

Authors:  Hitomi Imachi; Koji Murao; Shouji Ohtsuka; Mako Fujiwara; Tomie Muraoka; Hitoshi Hosokawa; Toshihiko Ishida
Journal:  Endocrine       Date:  2008-11-15       Impact factor: 3.633

8.  Increased skeletal muscle volume in women with familial partial lipodystrophy, Dunnigan variety.

Authors:  Hongzhao Ji; Paul Weatherall; Beverley Adams-Huet; Abhimanyu Garg
Journal:  J Clin Endocrinol Metab       Date:  2013-06-19       Impact factor: 5.958

9.  Body composition study by dual-energy x-ray absorptiometry in familial partial lipodystrophy: finding new tools for an objective evaluation.

Authors:  Cynthia M Valerio; Lenita Zajdenverg; José Egídio P de Oliveira; Patricia B Mory; Regina S Moyses; Amélio F Godoy-Matos
Journal:  Diabetol Metab Syndr       Date:  2012-08-31       Impact factor: 3.320

10.  Cardiac phenotype in familial partial lipodystrophy.

Authors:  Abdelwahab Jalal Eldin; Baris Akinci; Andre Monteiro da Rocha; Rasimcan Meral; Ilgin Yildirim Simsir; Suleyman Cem Adiyaman; Ebru Ozpelit; Nicole Bhave; Ramazan Gen; Banu Yurekli; Nilufer Ozdemir Kutbay; Zeynep Siklar; Adam H Neidert; Rita Hench; Marwan K Tayeh; Jeffrey W Innis; Jose Jalife; Hakan Oral; Elif A Oral
Journal:  Clin Endocrinol (Oxf)       Date:  2021-02-22       Impact factor: 3.523

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.